Jessica Walters

Anebulo Pharmaceuticals initiates a phase 1 trial for selonabant, targeting acute cannabis toxicity in children with promising IV treatment potential.

A phase 2 study reveals osavampator significantly reduces depression severity in adults with major depressive disorder, showing promise for treatment-resistant cases.

Esketamine nasal spray shows significant improvement in emotional blunting for treatment-resistant depression, offering hope for affected patients.

New study shows lumateperone (Caplyta) significantly improves symptoms in major depressive disorder with anxious distress, offering hope for treatment-resistant patients.

A groundbreaking trial reveals ANK3 as a potential genetic predictor for liafensine's effectiveness in treating resistant depression.

FDA clears accelerated deep TMS protocol for major depressive disorder, offering faster treatment with similar outcomes and fewer visits.

Timing hormone replacement therapy post menopause significantly influences Alzheimer disease risk, with early treatment offering protective benefits against cognitive decline.

Takeda's oveporexton shows promising results in treating narcolepsy type 1, significantly improving symptoms and quality of life in clinical trials.

FDA approves Amneal Pharmaceuticals' new long-acting injectable risperidone for schizophrenia, enhancing treatment options and potentially patient adherence.

Cognition Therapeutics advances zervimesine phase 2 trial, exploring its potential to slow cognitive decline in Alzheimer disease patients.

Achieve Life Sciences gains FDA acceptance for cytisinicline, a promising new drug for smoking cessation, showing significant abstinence rates in trials.

The FDA has approved the Leqembi subcutaneous autoinjector for at-home Alzheimer disease treatment.

A new mobile app has been found to reduce suicidal behavior post hospitalization in patients at high suicide risk.

NRX-100, a preservative-free ketamine, is granted expanded access for treatment of suicidal ideation in depression, offering new hope for patients.

BioXcel Therapeutics advances BXCL501 for at-home treatment of agitation in bipolar disorders and schizophrenia, aiming for FDA approval by 2026.

FDA approves Tonmya, a groundbreaking fibromyalgia treatment, offering hope for pain relief after 15 years without new options.

Researchers uncover how serotonin receptor 5-HT1A influences drug interactions, paving the way for faster, targeted psychiatric treatments.

Biogen's zuranolone gains positive opinion for treating postpartum depression, promising rapid symptom relief and potential EU approval by 2025.

Acumen Pharmaceuticals reveals a breakthrough blood assay that enhances Alzheimer’s trial efficiency and highlights sabirnetug's selectivity for toxic amyloid beta oligomers.

Explore the latest findings on neurotransmitter levels and innovative treatments for major depressive disorder, including TMS and cognitive impacts.

Stay informed on PTSD treatment insights, including complex PTSD recognition, diagnostic nuances, and the link between migraines and trauma.

Women with schizophrenia face increased breast cancer risks linked to long-term prolactin-raising antipsychotic use, highlighting the need for regular screenings and tailored treatment strategies.

A groundbreaking study reveals that reduced cortical thickness in the parahippocampus may indicate major depressive disorder and neuroticism traits.

Discover innovative strategies for early diagnosis and treatment of bipolar disorder, addressing challenges and exploring promising new therapies.

Discover groundbreaking schizophrenia treatment with xanomeline-trospium, targeting cholinergic pathways for improved symptoms and fewer side effects.

A groundbreaking study links antibiotic exposure to increased depression risk in adolescents, highlighting urinary analysis as a potential screening tool.

Researchers uncover a novel biomarker for major depressive disorder, linking regional homogeneity in fMRI to decreased cerebral blood flow and symptom severity.